Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Цетуксимаб в лечении ряда солидных опухолей: достижения и перспективы
Цетуксимаб в лечении ряда солидных опухолей: достижения и перспективы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biolog Ther 2007; 7 (2): 243–56.
2. Lenz H-J. Cetuximab in the management of colorectal cancer. Biologics: Targets Therapy 2007; I (2): 77–91.
3. Saltz LB, Meropol NJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8.
4. Lenz H-J, Mayer RJ et al. consistent reponse to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16s): Abstract 3536.
5. Jonker DJ et al. Proc of ASCO 2007; A LB-1.
6. Cunningham D, Humblet Y et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
7. Saltz L, Rubin et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (abstr 7).
8. Siena S et al. ASCO GI 2007; Abstract No. 353.
9. de Cerqueira Mathias C et al. ASCO GI 2007; Abstract No. 293.
10. Souglakos J, Kalykaki A et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2006; 1: 1–6.
11. Sobrero AF et al. Proc of ASCO 2007; Abstr LB-2.
12. Tabernero J et al. AACR 2007, Abstract #LB-352.
13. Pfeiffer P et al. ASCO GI 2007 (Abstract No. 305).
14. Arnold D, Höbler T, Dittrich C et al. Cetuximabin in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19: 1288–92.
15. Heinemann V, Fisher von Weikersthal L, Vehling-Kaiser U et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer: A study of german AIO CRC study group. JCO 2008; 26 (suppl.): abstract 4033.
16. Van Cutsem E, Nowacki M et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of pts with metastatic colorectal cancer. CRYSTAL trial. ASCO 2007; abstr. 4000.
17. Bokemeyer C et al. ASCO 2007; Abstract No. 4035.
18. Van Cutsem E, Humblet Y et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reactions on cetuximab standard dose treatment (EVEREST); preliminary PK and efficacy data of a randomized study. ASCO 2007; Abatr. 237.
19. Scartozzi M et al. J Clin Oncol 2004; 22: 4772–8.
20. Cappuzzo F et al. Ann Oncol 2008; 19: 717–23.
21. Van Cutsem E et al. ASCO 2008; abstr 2.
22. Bokemeyer C et al. ASCO 2008; abstr 4000.
23. Jonker DJ et al. N Engl Med 2007; 357: 2040–8.
24. Tejpar S et al. ASCO 2008; abstr 4001.
25. Cervantes A et al. ASCO 2008; abstr 4129.
26. Saltz L et al. ASCO GI Symposium: abstr. 169b. 2005.
27. Punt CJ et al. JCO2008; 26 (Suppl.): abstr LBA4011.
28. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
29. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
30. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman SA, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 2001; 797–860.
31. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to aplatinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17 (6): 418–24.
32. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–8.
33. Vermorken JB et al. ASCO 2007 (abstract and oral presentation №6091).
34. Baselga J et al. J Clin Oncol 2005; 23: 5568–77. Herbst R et al. J Clin Oncol 2005; 23: 5578–87.
35. Vermorken JB et al. J Clin Oncol 2007; 25: 2171–7.
36. Rosell R et al. Ann Oncol 2008; 19: 362–9.
37. Butts C et al. J Clin Oncol 2007; 25: 5777–85.
38. Lynch T et al. J Thorac Oncol 2007; 2 (Suppl. 4): S340–1.
39. Pirker R et al. J Clin Oncol 2008; 18S: Abstract 3.
40. Blumenschein GR Jr et al. J Clin Oncol 2008; 26 (May 20 suppl.): Abstract 7516.
41. Govindan R et al. J Clin Oncol 2008; 26 (May 20 suppl): Abstract 7518.
42. Coate LE et al. Ann Oncol 2006; 17 (Suppl. 9): abstr794P.
2. Lenz H-J. Cetuximab in the management of colorectal cancer. Biologics: Targets Therapy 2007; I (2): 77–91.
3. Saltz LB, Meropol NJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8.
4. Lenz H-J, Mayer RJ et al. consistent reponse to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16s): Abstract 3536.
5. Jonker DJ et al. Proc of ASCO 2007; A LB-1.
6. Cunningham D, Humblet Y et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
7. Saltz L, Rubin et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (abstr 7).
8. Siena S et al. ASCO GI 2007; Abstract No. 353.
9. de Cerqueira Mathias C et al. ASCO GI 2007; Abstract No. 293.
10. Souglakos J, Kalykaki A et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2006; 1: 1–6.
11. Sobrero AF et al. Proc of ASCO 2007; Abstr LB-2.
12. Tabernero J et al. AACR 2007, Abstract #LB-352.
13. Pfeiffer P et al. ASCO GI 2007 (Abstract No. 305).
14. Arnold D, Höbler T, Dittrich C et al. Cetuximabin in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19: 1288–92.
15. Heinemann V, Fisher von Weikersthal L, Vehling-Kaiser U et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer: A study of german AIO CRC study group. JCO 2008; 26 (suppl.): abstract 4033.
16. Van Cutsem E, Nowacki M et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of pts with metastatic colorectal cancer. CRYSTAL trial. ASCO 2007; abstr. 4000.
17. Bokemeyer C et al. ASCO 2007; Abstract No. 4035.
18. Van Cutsem E, Humblet Y et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reactions on cetuximab standard dose treatment (EVEREST); preliminary PK and efficacy data of a randomized study. ASCO 2007; Abatr. 237.
19. Scartozzi M et al. J Clin Oncol 2004; 22: 4772–8.
20. Cappuzzo F et al. Ann Oncol 2008; 19: 717–23.
21. Van Cutsem E et al. ASCO 2008; abstr 2.
22. Bokemeyer C et al. ASCO 2008; abstr 4000.
23. Jonker DJ et al. N Engl Med 2007; 357: 2040–8.
24. Tejpar S et al. ASCO 2008; abstr 4001.
25. Cervantes A et al. ASCO 2008; abstr 4129.
26. Saltz L et al. ASCO GI Symposium: abstr. 169b. 2005.
27. Punt CJ et al. JCO2008; 26 (Suppl.): abstr LBA4011.
28. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
29. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
30. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman SA, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 2001; 797–860.
31. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to aplatinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17 (6): 418–24.
32. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–8.
33. Vermorken JB et al. ASCO 2007 (abstract and oral presentation №6091).
34. Baselga J et al. J Clin Oncol 2005; 23: 5568–77. Herbst R et al. J Clin Oncol 2005; 23: 5578–87.
35. Vermorken JB et al. J Clin Oncol 2007; 25: 2171–7.
36. Rosell R et al. Ann Oncol 2008; 19: 362–9.
37. Butts C et al. J Clin Oncol 2007; 25: 5777–85.
38. Lynch T et al. J Thorac Oncol 2007; 2 (Suppl. 4): S340–1.
39. Pirker R et al. J Clin Oncol 2008; 18S: Abstract 3.
40. Blumenschein GR Jr et al. J Clin Oncol 2008; 26 (May 20 suppl.): Abstract 7516.
41. Govindan R et al. J Clin Oncol 2008; 26 (May 20 suppl): Abstract 7518.
42. Coate LE et al. Ann Oncol 2006; 17 (Suppl. 9): abstr794P.
Авторы
Н.С.Бесова, С.В.Хохлова, И.С.Романов, В.А.Горбунова, Е.Г.Матякин
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
ГУ РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.